The overall Objective of Biospecimens Accessioning and Processing Shared Resource (BAP) is to provide a central facility to electronically accession and process biospecimens intended for research by Cancer Center members.
The Specific Aims of the Shared Resource are to 1) provide electronic accessioning of biospecimens into a central Research Specimen Database, 2) to process the specimens appropriately according to their projected end use, 3) to provide nucleic acid extraction services, 4) to provide cryopreservation of mononuclear cells and EBV immortalization of B lymphocytes, and 5) to provide consultative services and specific expertise to Cancer Center investigators. Biospecimens accessioned through this resource include solid tissues as well as whole blood and other body fluids. Blood specimens are processed for nucleic acid extraction, future or immediate EBV immortalization of mononuclear cells, and/or frozen storage as plasma, serum or buffy coats. Fresh solid tissues are dissected and frozen in liquid nitrogen or freezing medium. One of the most valuable contributions of the BAP resource is the specimen annotation that is entered into the Research Laboratory Information System at the time of specimen accessioning and subsequently utilized for timely and appropriate retrieval of archived specimens. During the current funding period, BAP has developed substantial automation which has increased sample capacity without increased cost to investigators. Together, the electronic biospecimen accessioning combined with basic specimen processing, EBV immortalization, and nucleic acid extraction services have created a powerful, synergistic Shared Resource critical for support of translations!, epidemiologic and basic research of Cancer Center members. In 2007, the BAP Shared Resource processed over 1,700 cryopreservations and EBV transformations and extracted DNA from over 10,000 biospecimens for over 30 Cancer Center investigators.
|Wallace, Sumer K; Halverson, Jessica W; Jankowski, Christopher J et al. (2018) Optimizing Blood Transfusion Practices Through Bundled Intervention Implementation in Patients With Gynecologic Cancer Undergoing Laparotomy. Obstet Gynecol 131:891-898|
|Shrestha, Shikshya; Zhang, Cheng; Jerde, Calvin R et al. (2018) Gene-Specific Variant Classifier (DPYD-Varifier) to Identify Deleterious Alleles of Dihydropyrimidine Dehydrogenase. Clin Pharmacol Ther 104:709-718|
|Hu, G; Dasari, S; Asmann, Y W et al. (2018) Targetable fusions of the FRK tyrosine kinase in ALK-negative anaplastic large cell lymphoma. Leukemia 32:565-569|
|Geller, James I; Fox, Elizabeth; Turpin, Brian K et al. (2018) A study of axitinib, a VEGF receptor tyrosine kinase inhibitor, in children and adolescents with recurrent or refractory solid tumors: A Children's Oncology Group phase 1 and pilot consortium trial (ADVL1315). Cancer 124:4548-4555|
|Luchtel, Rebecca A; Dasari, Surendra; Oishi, Naoki et al. (2018) Molecular profiling reveals immunogenic cues in anaplastic large cell lymphomas with DUSP22 rearrangements. Blood 132:1386-1398|
|Oishi, Naoki; Brody, Garry S; Ketterling, Rhett P et al. (2018) Genetic subtyping of breast implant-associated anaplastic large cell lymphoma. Blood 132:544-547|
|DuBois, Steven G; Mosse, Yael P; Fox, Elizabeth et al. (2018) Phase II Trial of Alisertib in Combination with Irinotecan and Temozolomide for Patients with Relapsed or Refractory Neuroblastoma. Clin Cancer Res 24:6142-6149|
|Farber, Benjamin A; Lalazar, Gadi; Simon, Elana P et al. (2018) Non coding RNA analysis in fibrolamellar hepatocellular carcinoma. Oncotarget 9:10211-10227|
|Lu, Yingchang; Beeghly-Fadiel, Alicia; Wu, Lang et al. (2018) A Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer Risk. Cancer Res 78:5419-5430|
|Dasari, Surendra; Newsom, Sean A; Ehrlicher, Sarah E et al. (2018) Remodeling of skeletal muscle mitochondrial proteome with high-fat diet involves greater changes to ?-oxidation than electron transfer proteins in mice. Am J Physiol Endocrinol Metab 315:E425-E434|
Showing the most recent 10 out of 1129 publications